Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $50.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
